Inhibition of the proteasome induces cell cycle arrest and apoptosis in mantle cell lymphoma cells

Summary. Mantle cell lymphoma (MCL) is a distinctive non‐Hodgkin's lymphoma subtype, characterized by overexpression of cyclin D1 as a consequence of the chromosomal translocation t(11;14)(q13;q32). MCL remains an incurable disease, combining the unfavourable clinical features of aggressive and indolent lymphomas. The blastic variant of MCL, which is often associated with additional cytogenetic alterations, has an even worse prognosis and new treatment options are clearly needed. The present study investigated the effect of a specific proteasome inhibitor, lactacystin, on cell cycle progression and apoptosis in two lymphoma cell lines harbouring the t(11;14)(q13;q32) and additional cytogenetic alterations, including p53 mutation (NCEB) and p16 deletion (Granta 519). Granta cells were more susceptible to inhibition of the proteasome with respect to inhibition of proliferation and apoptosis induction. No changes were observed in the expression levels of the G1 regulatory molecules cyclin D1 and cdk4, but cell cycle arrest and apoptosis induction was accompanied by accumulation of the cdk inhibitor p21 in both cell lines. Increased p53 expression was only observed in Granta cells with wild‐type p53. Cleavage of procaspase‐3 and ‐9 was observed but cleavage of procaspase‐8 was not involved in apoptosis induction. The proapoptotic effect of lactacystin was reversed by pretreatment with the pancaspase inhibitor zVAD.fmk. Lactacystin was also effective in inducing apoptosis in lymphoma cells from MCL patients. We conclude that inhibition of the proteasome might be a promising therapeutic approach for this incurable disease.

[1]  R. Millikan,et al.  Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  E. Campo,et al.  variants of mantle cell lymphoma (MCL): implications for pathogenesis Sequestration of p27Kip1 protein by cyclin D1 in typical and blastic , 2013 .

[3]  Beverly S Mitchell,et al.  Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  X. Zhang,et al.  Ubiquitin/Proteasome-dependent Degradation of D-type Cyclins Is Linked to Tumor Necrosis Factor-induced Cell Cycle Arrest* , 2002, The Journal of Biological Chemistry.

[5]  JB Almond,et al.  The proteasome: a novel target for cancer chemotherapy , 2002, Leukemia.

[6]  J. Gribben,et al.  Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Manfredi,et al.  Multiple roles of the tumor suppressor p53 , 2002, Current opinion in oncology.

[8]  B. Branger,et al.  Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype , 2001, Leukemia.

[9]  I. Herr,et al.  Cellular stress response and apoptosis in cancer therapy. , 2001, Blood.

[10]  R. Heilig,et al.  A new recurrent and specific cryptic translocation, t(5;14)(q35;q32), is associated with expression of the Hox11L2 gene in T acute lymphoblastic leukemia , 2001, Leukemia.

[11]  H. Hoefler,et al.  p27Kip1 Immunostaining for the Differential Diagnosis of Small B-Cell Neoplasms in Trephine Bone Marrow Biopsies , 2001, Modern Pathology.

[12]  A. Hunter,et al.  Proteasome inhibitor-induced apoptosis of B-chronic lymphocytic leukaemia cells involves cytochrome c release and caspase activation, accompanied by formation of an ∼700 kDa Apaf-1 containing apoptosome complex , 2001, Leukemia.

[13]  J. Leonard,et al.  Biology and management of mantle cell lymphoma , 2001, Current opinion in oncology.

[14]  P. R. Yew,et al.  Ubiquitin‐mediated proteolysis of vertebrate G1‐ and S‐phase regulators , 2001, Journal of cellular physiology.

[15]  P. Elliott,et al.  The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. , 2001, Cancer research.

[16]  M. Vu,et al.  Proteasomes Modulate Balance Among Proapoptotic and Antiapoptotic Bcl-2 Family Members and Compromise Functioning of the Electron Transport Chain in Leukemic Cells1 , 2001, The Journal of Immunology.

[17]  S-G Hwang,et al.  Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition , 2000, Leukemia.

[18]  S. Ōmura,et al.  Deregulation of the ubiquitin system and p53 proteolysis modify the apoptotic response in B-CLL lymphocytes. , 2000, Blood.

[19]  Shigeo Nakamura,et al.  Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma , 2000 .

[20]  M. Seto,et al.  Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma. , 2000, Blood.

[21]  W. Telford,et al.  Proliferative response of mantle cell lymphoma cells stimulated by CD40 ligation and IL-4 , 2000, Leukemia.

[22]  M Chilosi,et al.  Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. , 2000, Blood.

[23]  G Flandrin,et al.  The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  S Omura,et al.  Increased sensitivity of CLL‐derived lymphocytes to apoptotic death activation by the proteasome‐specific inhibitor lactacystin , 1999, British journal of haematology.

[25]  E. Sausville,et al.  Proteasome inhibitors: a novel class of potent and effective antitumor agents. , 1999, Cancer research.

[26]  M. Grever,et al.  Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. , 1998, Cancer research.

[27]  P. Guldberg,et al.  Concurrent disruption of cell cycle associated genes in mantle cell lymphoma: a genotypic and phenotypic study of cyclin D1, p16, p15, p53 and pRb , 1998, Leukemia.

[28]  Sanjeev Sharma,et al.  A pivotal role of cyclin D3 and cyclin-dependent kinase inhibitor p27 in the regulation of IL-2-, IL-4-, or IL-10-mediated human B cell proliferation. , 1998, Journal of immunology.

[29]  E. Campo,et al.  Mantle cell lymphomas lack expression of p27Kip1, a cyclin-dependent kinase inhibitor. , 1998, The American journal of pathology.

[30]  S. Schreiber,et al.  Lactacystin, Proteasome Function, and Cell Fate* , 1998, The Journal of Biological Chemistry.

[31]  H. Müller-Hermelink,et al.  Cyclin D1 expression in mantle cell lymphoma is accompanied by downregulation of cyclin D3 and is not related to the proliferative activity. , 1997, Blood.

[32]  H. Drexler Activation of the cell death program by inhibition of proteasome function. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[33]  C. Sherr Cancer Cell Cycles , 1996, Science.

[34]  N. Harris,et al.  Expression of the Retinoblastoma Protein in Low-Grade B-Cell Lymphoma: Relationship to Cyclin D1 , 1996 .

[35]  W. Chan,et al.  p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. , 1996, Blood.

[36]  P. Beer-Romero,et al.  Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. , 1995, Science.

[37]  H. Koeffler,et al.  Role of the cyclin-dependent kinase inhibitors in the development of cancer. , 1995, Blood.

[38]  H Stein,et al.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.

[39]  C. M. Steel,et al.  Characterization of a new non-Hodgkin's lymphoma cell line (NCEB-1) with a chromosomal (11:14) translocation [t(11:14)(q13;q32)]. , 1988, Blood.

[40]  G. Cohen,et al.  Proteasome inhibitor-induced apoptosis of B-chronic lymphocytic leukaemia cells involves cytochrome c release and caspase activation, accompanied by formation of an approximately 700 kDa Apaf-1 containing apoptosome complex. , 2001, Leukemia.

[41]  M. Seto,et al.  Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma. , 2000, Blood.

[42]  W. Baumeister,et al.  The 26S proteasome: a molecular machine designed for controlled proteolysis. , 1999, Annual review of biochemistry.

[43]  J. Gribben,et al.  High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  E. Campo,et al.  Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas. , 1997, Blood.

[45]  J. Bartek,et al.  Potential role for concurrent abnormalities of the cyclin D1, p16CDKN2 and p15CDKN2B genes in certain B cell non-Hodgkin’s lymphomas. Functional studies in a cell line (Granta 519) , 1997, Leukemia.

[46]  N. Harris,et al.  Expression of the retinoblastoma protein in low-grade B-cell lymphoma: relationship to cyclin D1. , 1996, Blood.

[47]  A. López-Guillermo,et al.  PRAD-1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. , 1994, Blood.